₨ Official source-observed price
PKR 132,267.99
1's
PKR 132,267.99 / vial/unit
✓ Official DRAP price source observed · Source checked 2026-08-27
Price Intelligence
Equivalent price position
Same generic · strength · dosage form · compatible unitPrice Intelligence PRO →
This brandPKR 132,267.99/ vial/unit
Price position19% below medianvs like-for-like peer median
Peer comparators2current-price listings
🔒
MedInfoBase Pharma Pro
View Price Intelligence PRO
Unlock the full competitive price benchmark
See the exact peer median, min/max and quartiles, product rank, price percentile and the complete like-for-like competitor table.
Rank & percentilePeer medianFull competitor listPortfolio intelligence
Price-position comparison uses current official listed prices normalized to compatible units. It is a price benchmark, not a measure of sales, demand, prescription volume or market share.
Product details
- Generic
- Bevacizumab
- Therapeutic area
- Oncology & immunology
- Drug class
- Antineoplastic medicines
- ATC
- L01
- Strength
- 400 mg/16 mL
- Dosage form
- Injection
- Pack
- 1's
- Registration no.
- 105574
- Price record verified
- 2026-08-27
- Latest DRAP source check
- 2026-08-27 02:56
Manufacturer
Explore this manufacturer's complete MedInfoBase portfolio, generics and current listed prices.
View company portfolio →Traceability
Official price history
| Amount | Effective from | Verified | Source | Status |
|---|---|---|---|---|
| PKR 132,267.99 | 2026-07-23 | 2026-08-27 | DRAP PharmaPrice Index | Current |
Same generic
Other listed brands
ABEVMY 100 mg/4 mLAGP Limited · PKR 25,715.62Abevmy 400 400 mg/16 mL (25 mg/mL)AGP LimitedArketin 100 mg/4 mLRA Healthcare (SMC-Pvt) Ltd · PKR 17,674.07Avastin 400 mg/16 mLRoche Pakistan Ltd · PKR 236,486.52Avastin 100 mg/4 mLRoche Pakistan Ltd · PKR 59,483.08Avastin 400 mg/16 mLRoche Pakistan Ltd · PKR 236,486.52BAZUMAB 100 mg/4 mLHilton Pharma (Pvt) Limited. · PKR 23,067.95BAZUMAB 400 mg/16 mLHilton Pharma (Pvt) Limited. · PKR 91,711.79
Evidence note: “Source observed” means MedInfoBase captured the record from an official DRAP source; it does not by itself mean the product registration was independently matched in the DRAP registry. Price note: Unit-price comparisons are informational calculations from official-source pack prices and normalized pack quantities. A pharmacy's transaction price may differ. Verify current regulatory and product information before professional use.
Cite this record
Medicine record · DRAP registration 105574MedInfoBase. (2026). Cizumab 400 mg/16 mL Injection (1's), The Searle Company Limited — registration and price record [Data set]. MedInfoBase. Retrieved September 18, 2026, from https://medinfobase.com/brand/cizumab-400-mg-16-ml-105574-1s-the-searle-company-limited-28040/ Data observed 27 August 2026. Source: DRAP PharmaPrice Index. DRAP registration 105574.
MedInfoBase. Cizumab 400 mg/16 mL Injection (1's), The Searle Company Limited — registration and price record [Internet]. Islamabad: MedInfoBase; 2026 [cited 2026 Sep 18]. Available from: https://medinfobase.com/brand/cizumab-400-mg-16-ml-105574-1s-the-searle-company-limited-28040/ Data observed 27 August 2026. Source: DRAP PharmaPrice Index. DRAP registration 105574.
MedInfoBase (2026) Cizumab 400 mg/16 mL Injection (1's), The Searle Company Limited — registration and price record. Available at: https://medinfobase.com/brand/cizumab-400-mg-16-ml-105574-1s-the-searle-company-limited-28040/ (Accessed: 18 September 2026).
"Cizumab 400 mg/16 mL Injection (1's), The Searle Company Limited — registration and price record." MedInfoBase, 2026, https://medinfobase.com/brand/cizumab-400-mg-16-ml-105574-1s-the-searle-company-limited-28040/. Accessed 18 Sep 2026.
MedInfoBase. 2026. "Cizumab 400 mg/16 mL Injection (1's), The Searle Company Limited — registration and price record." Accessed September 18, 2026. https://medinfobase.com/brand/cizumab-400-mg-16-ml-105574-1s-the-searle-company-limited-28040/.
Price and registration data on this page were observed on 27 August 2026. Records change over time, so please cite the observation date alongside the access date.